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Combined Treatment With Laser and Topical Eﬂornithine is more effective than Laser
Treatment Alone for Removing Unwanted Facial Hair—A Placebo-Controlled Trial
Eileen Tan, Iltefat Hamzavi, Jerry Shapiro, Harvey Lui
Division of Dermatology, University of British Columbia, Vancouver, Canada
Background and Objectives: Topical eflornithine and pulsed lasers remove unwanted
hair by different mechanisms. The objective of this study was to determine whether combined
treatment with eflornithine and a pulsed infrared laser would induce greater hair reduction
than laser treatment alone.
Materials and Methods: This was a placebo controlled, double-blind, right-left bilateral
study involving female patients undergoing up to six monthly laser hair removal sessions to
the entire upper lip with a 755 nm, long-pulse (10–40 msec) alexandrite laser. Throughout the
study period, each patient was randomly assigned to apply topical eflornithine 13.9% cream
to one side of the upper lip, and a placebo vehicle cream to the contralateral side twice daily.
The degree of hair removal for each side of the lip was assessed monthly on a semiquan-
titative; four point ordinal scale by a physician investigator.
Results: 33 patients were enrolled in the study and 31 completed all the required laser visits.
Two patients were lost to follow up and one dropped out due to hyperpigmentation following
treatment with the laser. More rapid hair reduction was observed with combined laser-efl-
ornithine treated side. Eighty percent or more hair reduction was achieved two treatment
cycles faster compared to laser only treatment side. For the laser only treatment sides,
complete or almost complete hair removal was achieved in 61.3% (19/31), as compared to
93.5% (29/31) for laser combined with eflornithine.
Conclusions: Hair removal with combined eflornithine and laser is superior to laser alone for
removing unwanted facial hair.
Effectiveness of Finasteride on Patients With Male Pattern Baldness Who Have Different
Androgen Receptor Gene Polymorphism
Kazuhiro Kobayashi, Nagaoki Wakisaka, Yuh-ichi Taira, Masahiro Ishikawa, Yoshio Nakamizo,
Masashi Uwabu, Yasutaka Fukuda, Yasuyuki Taguchi, Takanori Hama, and Masaya Kawakami
NPO Future Medical Laboratory, Tokyo, Japan
Objectives: Most of male pattern baldness (MPB) patients have androgen-dependent trait
although it is under the control of multiple genes, such as genes for androgen receptor (AR),
IGF-1 and dihydrotestosterone regulations. A 5 alpha-reductase inhibitor, finasteride, is ef-
fective on MPB although there is a variation in the efficacy of this drug among the MPB
patients. From the functional mechanism of this drug, it is thought to be effective on MBP
caused by hyper-function of AR. Association of polymorphism in the first exon of AR gene
with MPB has been demonstrated by some authors (Sawaya and Salita, 1998; Ellis et al,
2001).We have found that there is a correlation between the symptom level of MPB and the
CAG and GGC repeat length in AR gene. To investigate relationship between the effective-
ness of finasteride and the AR gene polymorphism, we determined the number of triplet
repeats in AR gene of patients.
Methods: Blood cell DNA was extracted from 740 MPB patients (19–62 y) and 54 non-bald
men (44–72 y). After PCR of the first exon of AR gene, the number of CAG and GGC triplets
was determined by conventional sequencing or transcriptional sequencing method. AGGCCT
sequence was determined using two different Stu I restriction enzymes.
Results and Conclusions: Effectiveness of finasteride in each patient was expressed as the
improvement point of symptom derived from Hamilton-Norwood typing. Number of the triplet
repeats (CAGþGGC) was plotted against the symptom points. There was a broad correlation
between these variables. Finasteride was more effective for the improvement of MPB in
patients with shorter triplet regions of AR gene. These cases may be caused by hyper-
function of AR. On the other hand, this drug was less effective in certain cases with longer
triplet repeats. They are thought to result from non-androgenic mechanism. This sort of
analysis may help the drug choice for MPB patients.
Clinical Significance of the HLA-DR11 Positive Subset in Patients With Alopecia Aerata
C. Marques Da Costa, J. J. Stene, E Dupont,w M. Vandercruys,w M. Hidajat,w M. Andrienw
Dept. of Dermatology (St. Pierre Hosp.); wImmunology (Erasme Hosp.) Universite´ Libre de
Bruxelles, Belgium
Many studies have shown an association of alopecia aerata (AA) with HLA-DR11. In view of
the fact that in several autoimmune diseases such as psoriasis and diabetes, the existence of
an HLA association indicates a clinical evolution (i.e. earlier onset of the disease) which is
different from the forms that are not associated with HLA, we investigated various parameters
in a group of 88 patients with severe AA. This included 32 DR11 positive and 56 DR11
negative patients. Compared to the frequency (22%) of DR11 in 99 healthy subjects be-
longing to the same ethnic background, a significant association (p¼ 0.01; RR¼2.1) was
found. However the analysis by DNA subtyping of the frequency of the various DR allotypes
revealed a similar distribution in the diseased and in the control groups. In the DR11 positive
subset, age of onset (16.4  2.6 years) occurred significantly earlier than in the DR11 neg-
ative subset (27.3  2.3 years ; p¼0.01). The analysis of the clinical course of patients was
performed by considering two groups of patients, those with severe AU/AT forms and those
not belonging to this peculiar subset. There was a slight although not significant excess of
severe AU/AT cases in the DR11 pos group (n¼ 17; 53%) as compared to the DR11 negative
which included only 24 patients (43%).
It is concluded that the DR11 mediated form of AA includes patients with an earlier onset of
disease, the later involving a slightly increased proportion of severe forms, an observation
compatible with the existence of non HLA genes in addition to HLA genes in the development
of the disease.
Deﬁning a Role for Hairless by Analytical Comparison of Differential Gene Expression
Hyunmi Kim, Andrew Engelhard, Karima Djabali, Andrey Panteleyev, and Angela M. Chris-
tiano
Departments of Dermatology and Genetics & Development, Columbia University, College of
Physicians & Surgeons, New York, NY, USA
Mutations in the hairless (hr) gene in mouse and humans results in the loss of hair and the
integrity of the hair follicle. The hr protein has been suggested to act as a transcription factor
with a critical role during catagen, as indicated by hr mutations in humans and mouse mod-
els. hr is transcriptionally regulated by thyroid hormone in the brain, however, recent data
from our laboratory indicates that it is not the major regulator of hr expression in the skin.
Mouse models of other nuclear receptors such as knockouts of VDR and RXR suggest a
possible regulatory pathway for hr, however, we have not found an interaction between VDR
and RXR using multiple biochemical approaches.
In order to better understand the function of hr, we took a global, data driven approach
toward determining hairless target genes and the possible pathway(s) hr functions. We used
Affymetrix microarrays to compare the differential gene expression profiles of wild type
mouse day 2 epidermis and rhino (rhhr/) mouse day 2 epidermis. Using MAS5 and IBM
Genes@Work software for supervised analysis, stringent parameters of two-fold or greater
statistically significant values resulted in a list of 58 differentially expressed genes. 51 of these
genes were found to be up-regulated by hr, while 7 genes were found to be down-regulated
by hr. hr itself was found to be differentially regulated between these two populations, serving
as an internal control. These genes can be organized into 9 main categories: extracellular
matrix (12), cytoskeletal organization (4), cell cycle (3), signaling (4), proteolysis and pep-
tidolysis (5), metabolism (4), transcriptional and translational regulation (5), unknown cDNA
clones (5) and other (16). Validation of the array has been performed using Real-Time PCR,
in situ hybridization, and immunoflourescence, confirming the expression of these genes in
murine neonate epidermis. Using pathway building software, these differentially genes were
analyzed for possible pathway or regulatory relationships to one another as well as to hr in
order to place hr in the context of a regulatory pathway.
Substantial Sex-Dependent Differences in the Response of Human Scalp Hair Follicles to
Estrogen Stimulation in vitro Advocate Gender-Tailored Management of Female versus
Male Pattern Balding
F. Conrad, U. Ohnemus, B. Gerstmayer,w A. Bosio,w A. Bettermann, E. Bodo, R. Paus
Dept. of Dermatology, University Hospital Hamburg-Eppendorf, University of Hamburg, D-
20246 Hamburg, Germany; wFa memorec, Cologne, Germany
Estrogens (17--estradiol, E2) profoundly modulate hair growth, acting largely as hair growth
inhibitors. Here, we investigated how E2 affects the growth, estrogen receptor (ER) expres-
sion and gene regulation of male versus female human scalp hair follicles in vitro. Anagen VI
follicles from frontotemporal scalp skin were microdissected and organ-cultured for up to 9
days in the presence of E2 (1–100 nM). Immunohistochemistry was performed for ER-
expression, known to be predominant in human scalp hair follicles, and E2-responsive genes
in organ-cultured human scalp hair follicles (48 h, 10 nM) were explored by cDNA microarray,
using a commercial skin focus chip (memorec, Cologne).
Hair shaft elongation of female hair follicles was significantly inhibited by 1–100 nM E2,
starting on day 5 to day 9 of the culture period (1 nM, po0.001). In striking contrast, hair shaft
elongation in male hair follicles was significantly stimulated by 1–100 nM E2 during the whole
culture period (10 nM, po0.001). This correlated with a significant increase of proliferating
(Ki67þ ) hair matrix keratinocytes on day 9 (10 nM, po0.05). As in female frontotemporal
follicles, the duration of anagen was slightly prolonged in E2-treated male hair follicles com-
pared to controls. The distribution pattern of ER-immunoreactivity also substantially differed
between male and female hair follicles after 48 h culture (female: predominant in the dermal
papilla, male: predominant in matrix cells). Of 1300 genes tested, more than 600 E2-respon-
sive genes (o0.5fold suppressed or 41.5fold stimulated) were detected in human hair fol-
licles. Several genes were modulated in both sexes (e.g. down-regulation of SPP1; up-
regulation of K6HF). In addition, sex-dependent differences in E2-mediated gene regulation
were detected (e.g., for BMP7, EPS8 [belongs to the epidermal growth factor receptor-
pathway], CYR61[homolog of insulin-like growth facto-binding protein], FOS-like antigen2).
In conclusion, this study reveals substantial sex-dependent differences in the response of
frontotemporal human scalp hair follicles to E2, which are likely based on significant E2-
dependent gene regulation differences. Recognition and systematic dissection of these dif-
ferential E2 responses will be crucial for the development of more effective, gender-tailored
management strategies for female versus male pattern balding.
Standardized Protocols Allow Specific Targeting of Vellus Hair Follicles and Terminal
Hair Follicles, Respectively
A. Vogt, R Toll, S. Gontschoukow, S. Hadam, J. Lademann, U. Blume-Peytavi
Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology,
Charite´—University Medicine Berlin, Germany
In intact skin, the stratum corneum considerably impairs interfollicular penetration processes.
This tight barrier, however, is interrupted in the infrainfundibular parts of the human hair
follicles which may represent not only a reservoir, but also a major entry point for topically
applied compounds. Selective follicular targeting allows to direct active compounds at high
concentrations into the hair follicles and may lead to new therapeutic approaches in the
treatment of hair disorders. Microspheres, loaded with fluorescent dyes for proof of concept
studies or with active compounds for therapeutic use, are valuable tools for efficient drug
delivery into the hair follicle. The aim of this project was to standardize the application method
of microparticles in aqueous and alcoholic solutions ranging from 6 mm to 40 nm in size on
fresh human skin samples. Infrared irradiation, massage, tape stripping and cyanoacrylate
tape stripping were assessed to optimize follicular penetration. The microspheres were lo-
calized by fluorescence microscopy on cryosections.
Depending on size and formulation, microspheres allow to target different sites of the hair
follicle, and targeting of different hair follicle types can be achieved by minor modifications of
the application protocol.
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